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BACKGROUND: Proviral integration Moloney virus (PIM) kinases (PIM1, 2 and 3) are overexpressed in several tumour types and
contribute to oncogenesis. AZD1208 is a potent ATP-competitive PIM kinase inhibitor investigated in patients with recurrent or
refractory acute myeloid leukaemia (AML) or advanced solid tumours.
METHODS: Two dose-escalation studies were performed to evaluate the safety and tolerability, and to deﬁne the maximum
tolerated dose (MTD), of AZD1208 in AML and solid tumours. Secondary objectives were to evaluate the pharmacokinetics,
pharmacodynamics (PD) and preliminary efﬁcacy of AZD1208.
RESULTS: Sixty-seven patients received treatment: 32 in the AML study over a 120–900mg dose range, and 25 in the solid tumour
study over a 120–800mg dose range. Nearly all patients (98.5%) in both studies experienced adverse events, mostly gastrointestinal
(92.5%). Dose-limiting toxicities included rash, fatigue and vomiting. AZD1208 was not tolerated at 900 mg, and the protocol-
deﬁned MTD was not conﬁrmed. AZD1208 increased CYP3A4 activity after multiple dosing, resulting in increased drug clearance.
There were no clinical responses; PD analysis showed biological activity of AZD1208.
CONCLUSIONS: Despite the lack of single-agent clinical efﬁcacy with AZD1208, PIM kinase inhibition may hold potential as an
anticancer treatment, perhaps in combination with other agents.
British Journal of Cancer (2018) 118:1425–1433; https://doi.org/10.1038/s41416-018-0082-1
INTRODUCTION
Proviral integration Moloney virus (PIM) kinases (PIM1, 2 and 3) are
a family of nuclear and cytoplasmic serine (S)/threonine (T) kinases
that regulate apoptosis and control cell cycle progression by
phosphorylating substrates such as Bcl-2 antagonist of cell death
(BAD),1,2 p21Cip1/WAF13 and cMyb.4
PIM kinases appear overexpressed in several tumour types,
contributing to oncogenesis.5,6 For example, PIM1 is over-
expressed in ~30% of haematopoietic malignancies, particularly
in acute myeloid leukaemia (AML) and acute lymphoblastic
leukaemia.7 PIM1 in T cells induces the formation of lymphoma
and increases the rate of lymphoma development in response to
Murine Leukaemia Virus.6 Furthermore, PIM1 and PIM2 are
overexpressed in haematological malignancies8,9 and solid
tumours.9,10
AZD1208 is a potent, ATP-competitive, pan-PIM kinase inhibitor
designed to target PIM1, 2 and 3.11 It has been investigated in
preclinical models of AML and prostate cancer.12,13 In AML cell
lines, inhibition of cell growth by AZD1208 correlated with PIM1
expression. AZD1208 induced cell cycle arrest and apoptosis,
which were accompanied by dose-dependent reductions in levels
of phosphorylated BAD, 4E-BP1, p70S6K and S6 proteins.12
Here, we report the results of two parallel phase I dose-
escalation studies using the PIM kinase inhibitor, AZD1208, which
examined the safety, tolerability, pharmacokinetics (PK) and
preliminary efﬁcacy of AZD1208 in patients with recurrent or
refractory AML or advanced solid tumours.
MATERIALS AND METHODS
Study objectives
Both dose-escalation studies recruiting patients with AML
(ClinicalTrials.gov, NCT01489722) and advanced solid malignan-
cies (NCT01588548) were phase I, open-label, multicentre studies
designed to identify the maximum tolerated dose (MTD) and
evaluate the safety and tolerability of AZD1208 administered
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orally once daily (QD). Secondary objectives included evaluation of
the drug PK and preliminary evidence of efﬁcacy. The AML study
also explored pharmacodynamic (PD) biomarkers.
Patient eligibility
Prior to participation in either study, all patients signed an
informed consent document approved by the Institutional Review
Board at each site. Both studies were conducted according to the
Declaration of Helsinki.
For the AML study, eligible patients were ≥18 years of age with
relapsed/refractory AML, with AML secondary to myelodysplastic
syndromes or myeloproliferative neoplasm, or with chronic
myeloid leukaemia in blast phase. Patients were required to
have Eastern Oncology Cooperative Group Performance Status
(ECOG PS) 0–2 and be considered likely to complete at least
4 weeks of therapy.
For the solid tumour study, eligible patients were ≥18 years of
age and diagnosed with advanced solid tumours—including non-
Hodgkin lymphoma—refractory to standard therapies, or for
which no standard therapies exist. Eligible patients were required
to have ECOG PS 0–1, life expectancy of ≥12 weeks, and ≥1 lesion
that could be accurately assessed by Response Evaluation Criteria
in Solid Tumours (RECIST) v.1.1 using computed tomography (CT)
or magnetic resonance imaging.
Patients were excluded from both studies if they had
concomitant uncontrolled diseases, including uncontrolled
diabetes, high cholesterol and high white blood cell count
(>100,000/mm3). Prior allogeneic haematopoietic cell transplanta-
tion was allowed, as long as the patients were not still requiring
immunosuppression.
Treatment plan and study design
AML dose-escalation study. Conducted at three centres in the
USA and one in Canada. Dose escalation followed a conventional
3+ 3 design. The starting dose of AZD1208 was 120 mg QD orally
continuously in each 28-day cycle. In the ﬁrst cohort, dosing
between the ﬁrst and subsequent patients was staggered with a
7-day interval. Dose-escalation decisions were based on the safety
and tolerability data from ≥3 evaluable patients (or six if one of
the ﬁrst three patients experienced a dose-limiting toxicity [DLT]).
Evaluable patients must have received ≥75% of the speciﬁed
AZD1208 dose, or experienced a DLT, during the ﬁrst 28-day cycle.
AZD1208 could be escalated by up to 100% in subsequent cohorts
until one DLT was observed, after which succeeding doses were
escalated by up to 50%.
In the case of a DLT, the cohort was expanded to six patients. If
a DLT occurred in ≥2 patients within a cohort, the dose was
determined to be a non-tolerated dose (NTD) and dose escalation
was stopped.
Grade 3 or 4 toxicities not attributable to the disease or disease-
related processes under investigation, and occurring before the
end of Cycle 1, were considered DLTs. The following were also
considered DLTs: QTc prolongation (>500 ms; Fridericia’s correc-
tion) or an increase of >60 ms from baseline QTc to a QTc value
>480ms, conﬁrmed on repeat 48-h electrocardiogram (ECG);
Common Terminology Criteria for Adverse Events (CTCAE) grade 3
or 4 vomiting lasting >24 h, despite suitable antiemetics; grade 5
(death, unless clearly unrelated to therapy [e.g., accidental, due to
progressive disease]) or any other toxicity judged to be a DLT by
the Safety Review Committee; marrow aplasia continuing for
≥42 days in the absence of leukaemia.
The NTD was identiﬁed as the dose at which ≥2 DLTs occurred
in a given cohort. The MTD was deﬁned as the highest dose at
which <33% of six patients experienced a DLT.
Solid tumour dose-escalation study. Conducted at two UK centres
and one in Japan. Dose escalation followed a rolling six design.14
Patients received a single dose on Day 1 during Cycle 0, followed
by a 3-day washout period, after which multiple dosing was
initiated. Cycle 1 was a 21-day period from the ﬁrst dose of
multiple dosing.
The dose decisions for a cohort and deﬁnition for an
evaluable patient were the same as in the AML dose-escalation
study. DLTs were deﬁned as: QTc prolongation (>500 ms) or an
increase of >60 ms from baseline QTc to a QTc value >480 ms,
conﬁrmed on repeat 48-h ECG; haematological toxicity (≥grade 4
present for >4 days [including grade 4 thrombocytopenia,
regardless of duration]); anaemia, as deﬁned by haemoglobin
<6.5 g/dl (<4.0 mmol/l); febrile neutropenia (including grade 3
neutropenia and temperatures >38.5 °C); grade 3 thrombocyto-
penia with grade 3 haemorrhagic events; non-haematological
toxicity ≥CTCAE grade 3, including diarrhoea, nausea or vomiting
persisting for >3 days despite aggressive management; any other
toxicity greater than that at baseline, clinically signiﬁcant and/or
unacceptable, not responding to supportive care and resulting in
a disruption of the dosing schedule for >14 days.
Administration of AZD1208 began at 120mg QD, with
subsequent dosing levels adjusted based on emerging safety
and PD data.
Assessments
Safety. Safety and tolerability were assessed from the time of
informed consent until the end of follow-up (deﬁned as 30 and
28 days after study treatment was discontinued for the AML and
solid tumour studies, respectively) by evaluation of adverse events
(AEs), vital signs, ECGs and laboratory assessments. The CTCAE
(version 4.0) was utilised to grade all AE events.
PK sampling. The schedules for collection of blood and urine
samples for PK analyses in each cohort in both studies are
described in Supplementary Table 1. When necessary for clinical
response assessment in the AML study, a bone marrow sample for
PK analysis was collected at Cycle 1, Day 28.
In the solid tumour study, blood samples for
4β-hydroxycholesterol analysis were collected pre-dose at Cycle
0, Day 1; Cycle 1 (Day 8 and 15); and Cycle 2, Day 15.
The concentration of AZD1208 in plasma and urine was
determined by Covance, on behalf of Clinical Bioanalysis Alliance
at AstraZeneca R&D, using a bioanalytical method. A volume of
0.05 ml of K2EDTA human plasma sample was extracted by
liquid–liquid extraction using 0.7 ml of methyl tert-butyl ether.
Approximately 100 µl of the supernatant was transferred, evapo-
rated to dryness and reconstituted with 350 µl of 1:1
methanol:water, and a 5 µl injection was made to the high-
performance liquid chromatography (HPLC) column. HPLC separa-
tions were performed on a Phenomenex LUNA C18 (50 × 2mm,
5 µm) column using a mobile phase of 0.1% formic acid in
water (A) and 0.1% formic acid in acetonitrile (B) at a ﬂow rate of
0.6 ml/min and a column temperature of 40 °C. AZD1208-D5 was
used as the internal standard. Detection was performed in a Sciex
API4000 mass spectrometer, in a positive electrospray ionisation
mode, using multiple reaction monitoring detection
(AZD1208: 380.0–>248.1; AZD1208-D5: 385.0–>253.1).
PD sampling
AML dose-escalation study. For AZD1208 PD evaluations, bone
marrow aspirates were collected (pretreatment and Cycle 1, Day 1,
2–6 h following administration of AZD1208) and peripheral blood
samples were collected (pretreatment on Cycle 1, Day 1; and on-
treatment at Cycle 1, Day 1 at 3, 6 and 24 h post-dose; Cycle 1,
Day 14 at pre-dose, 3 and 6 h post-dose). Mononuclear cells were
isolated, and protein lysates prepared, for subsequent analysis of
phosphorylated BAD at S112 by MesoScale Discovery ELISA and
phosphorylation of 4E-BP1 at S65 by NanoPro immunoassay
[unpublished data: McEachern et al. 2018, manuscript in prepara-
tion]. Samples were considered evaluable when the baseline
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biomarker levels were above the background signal (as deﬁned by
buffer-only negative control samples) and within the linear range
of assay. Additionally, only blood samples containing detectable
blasts were considered for analysis.
Isolation of primary leukaemia cells for protein proﬁling. In the
AML study, a protein proﬁling analysis was carried out on primary
blasts obtained from peripheral blood of patients (n= 6) before
and during therapy with AZD1208. Due to time-sensitive aspects
of the analysis, only patients from the MD Anderson Cancer Center
(MDACC, Houston, TX, USA) were eligible. Whole blood was
collected in heparinised tubes. Leukaemia cells were then isolated
using Ficoll–Hypaque (speciﬁc gravity, 1.086; Life Technologies,
Grand Island, NY, USA) density gradient separation, as previously
described.15 Cell number and mean cell volume were determined
using a Coulter Channelyzer (Coulter Electronics, Hialeah, FL, USA).
Mutation analysis was determined for the AML study patients
using the ﬂuorescent multiplex polymerase chain reaction and
restriction digestion method, followed by capillary electrophoresis
at MDACC.
AML blasts isolated from patients during therapy with AZD1208
were harvested and submitted for reverse phase protein array
(RPPA) analysis to evaluate protein level changes across a set of
171 antibodies,16 graphed using GraphPad Prism software
(GraphPad Software, Inc., San Diego, CA, USA).
Tumour response. The antileukaemic activity in AML was accord-
ing to the International Working Group (IWG) response criteria for
AML.17 Response criteria were modiﬁed such that an M-1 marrow
was deﬁned as 1% to ≤5% and a partial response as >5% to 25%.18
In the solid tumour study, responses were evaluated using
RECIST v.1.1. Contrast-enhanced CTs of the chest, abdomen, pelvis
and neck were performed at screening (≤28 days before the start
of study treatment), every 6 weeks (±1 week) up to 12 weeks, and
then every 12 weeks (±1 week) until discontinuation of study
treatment or withdrawal of consent, starting from Day 1 of Cycle 1.
Statistical analysis
AEs were summarised by Medical Dictionary for Regulatory Activities
(MedDRA) system organ class, MedDRA preferred term and CTCAE
grade. Summary statistics of mean, median, standard deviation,
minimum, maximum and number of observations were used.
RESULTS
Baseline data and treatment overview
AML dose-escalation study. Patient demographics and baseline
characteristics were similar in each cohort and are shown in
Table 1.
A total of 55 patients were enrolled into the dose-escalation
phase of the AML study between 10 February 2012 and 13 May
2014, 32 of whom were assigned to treatment. The other 23
patients were screen failures. All patients assigned to treatment
received ≥1 dose of AZD1208 at: 120 mg, n= 4; 240 mg, n= 6;
480mg, n= 6; 700mg, n= 7; and 900 mg, n= 9. On Day 28 (Cycle
1 completion), 11 patients were receiving AZD1208 (n= 2 in each
of the 120, 480, 700 and 900 mg dose cohorts; 240 mg, n= 3).
Three patients completed Cycle 2 (n= 1 in each of the 480, 700
and 900mg dose cohorts). By Day 84, all patients had
discontinued treatment.
Among all dose levels, treatment duration ranged from
4–66 days (median range, 15–27 days). One patient in each of
the 240 mg (rash), 480 mg (stomatitis) and 700 mg (febrile
neutropenia) dose cohorts, and two patients in the 900 mg
cohort (one with hypotension, pyrexia and thrombocytopenia;
one with rash), had one dose interruption due to AEs. No
patients required dose reduction. All 32 eligible patients
eventually discontinued study treatment due to a lack of
Table 1. Patient baseline characteristics in the AML and solid tumour
dose-escalation studies
AML dose-escalation
study
n= 32
Solid tumour
dose-escalation study
n= 35
Age, years
Median 65 65
Range 18–89 28–81
Sex
Male 21 (65.6) 17 (48.6)
Female 11 (34.4) 18 (51.5)
Race
White 26 (81.3) 19 (54.3)
Asian 3 (9.4) 16 (45.7)
Other 3 (9.4) 0
Extent of disease at baseline
Locally advanced NA 13 (37.1)
Metastatic NA 31 (88.6)
Disease under study
Refractory AML
(primary only)
21 (65.6) NA
First relapse 3 (9.4) NA
Second relapse 4 (12.5) NA
Third or further relapse 4 (12.5) NA
ECOG PS
0 6 (18.8) 16 (47.1)
1 21 (65.6) 18 (52.9)
2 5 (15.6) 0
Prior therapy
Surgery NA 27 (77.1)
Radiotherapy 2 (6.3) 35 (100)
Chemotherapy, n (%),
median
32 (100), 4.0 34 (97.1), NA
Immuno-/hormonal
therapy
NA 6 (17.1)
Other systemic
anticancer therapya
2 (6.3) 0
Stem cell transplant 5 (15.6) NA
Molecular mutation status
FLT3
Detected 3 (9.4) NA
Not detected 12 (37.5) NA
Unknown 17 (53.1) NA
NPM1
Detected 0 NA
Not detected 12 (37.5) NA
Unknown 20 (62.5) NA
Cytogenetics
Normal 14 (43.8) NA
t (8:21) 1 (3.1) NA
Inv 16 or t (16:16) 1 (3.1) NA
Abnormalities of 5
and/or 7
7 (21.9) NA
Complex (>3
abnormalities)
8 (25.0) NA
Other 14 (43.8) NA
Data are n (%) unless otherwise stated. AML acute myeloid leukaemia,
ECOG PS Eastern Oncology Cooperative Group Performance Status, FLT3
FMS-like tyrosine kinase 3, NA not applicable, NPM1 nucleophosmin.
aDetails of ‘other systemic anticancer prior therapy’ are not known
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therapeutic response (n= 19, 59.4%), AEs (n= 8, 25.0%) and
patient’s decision (n= 5, 15.6%).
Solid tumour dose-escalation study. Patient demographics and
baseline characteristics were similar in each cohort and are shown
in Table 1. Overall, 43 patients were enrolled in the solid tumour
study between 17 July 2012 and 14 April 2014, 35 of whom were
assigned to treatment (120 mg, n= 3; 240mg, n= 7; 360 mg,
n= 6; 540mg, n= 7; 700 mg, n= 6; and 800mg, n= 6).
Twenty-one (60.0%) patients completed the Cycle 1, Day 21 DLT
evaluation period (120 mg, n= 3; 240 mg, n= 5; 360mg, n= 2;
540mg, n= 5; 700mg, n= 3; and 800mg, n= 3). Reasons for not
completing the DLT evaluation period were progressive disease
(n= 8, 22.9%), patient decision (n= 3, 8.6%) and AE (n= 3, 8.6%).
The median treatment duration was 41 days, but varied
considerably (range, 10–357 days). Mean duration was greater
for the lower doses (120–540 mg: 78–91 days) than the higher
doses (700 mg and 800 mg: 29–44 days). All 35 (100%) patients
eventually discontinued study treatment due to disease
progression (n= 23; 65.7%), patient decision to discontinue
(n= 8, 22.9%) or AEs (n= 4, 11.4%).
Safety and tolerability
AML dose-escalation study. AEs: Overall, 31 patients (96.9%)
experienced an AE (Table 2). Gastrointestinal disorders were the
most commonly reported AEs (n= 28, 87.5%), most frequently
nausea (n= 15, 46.9%) and diarrhoea (n= 14, 43.8%). AEs judged
by the investigator to be possibly related to AZD1208 occurred in
22 patients (68.8%), with the most common being nausea (n= 12,
37.5%), diarrhoea (n= 7, 21.9%), vomiting (n= 6, 18.8%) and
fatigue (n= 6, 18.8%). No clinically signiﬁcant ECG abnormalities
were observed. Seventy-ﬁve percent of patients (n= 24) experi-
enced a grade ≥3 AE, with febrile neutropenia (n= 9, 28.1%),
hypotension (n= 6, 18.8%) and pneumonia (n= 5, 15.6%) the
most commonly reported.
Serious AEs (SAEs) were reported in 71.9% (n= 23) of patients.
Febrile neutropenia (n= 8, 25.0%), hypotension, abdominal pain,
maculopapular rash and back pain (each n= 2, 6.3%) were SAEs
reported in >1 patient. Treatment-related SAEs occurred in ﬁve
(15.6%) patients: two in the 700mg dose cohort (one each of
Guillain–Barré syndrome [GBS] and increased blood creatinine)
and three in the 900mg dose cohort (one febrile neutropenia,
two rash).
In total, AZD1208 was discontinued in eight patients (25%), as a
result of SAEs and AEs (treatment-related and non-treatment-
related): 240mg, n= 1 (bacteremia [SAE] and peristomal ulcer
[AE]); 480 mg, n= 2 (vomiting [AE] and gingival pain [AE]); 700 mg,
n= 3 (lung infection, GBS and Escherichia spp. sepsis [SAEs]); and
900mg, n= 2 (acute coronary syndrome and rash [SAEs]). These
AEs and SAEs were considered treatment-related in four patients:
240mg, n= 1 (peristomal ulcer [AE]); 480mg, n= 1 (vomiting
[AE]); 700mg, n= 1 (GBS [SAE]); and 900 mg, n= 1 (rash [SAE]).
There were nine deaths during the study, all attributed by the
investigators to disease progression.
DLTs: DLTs were reported in ﬁve patients and occurred between
1–10 days after the start of treatment: 240 mg, n= 1 (peristomal
ulcer); 480 mg, n= 1 (fatigue); 700 mg, n= 1 (GBS); 900 mg, n= 2
(both rash) (Table 3). One patient with maculopapular rash was
rechallenged with AZD1208 at the same dose with no recurrence
of the DLT. The other DLTs of rash and GBS resulted in
discontinuation of AZD1208.
During the study, no cohort comprised the minimum
of six evaluable patients that was required to deﬁne
MTD (a total of 3/7 patients completed Cycle 1 at 700 mg).
MTD was not determined as the dose level below the NTD did
not contain the six evaluable patients required to deﬁne the
MTD of AZD1208.
Solid tumour dose-escalation study
AEs: All 35 patients reported ≥1 AE (Table 4). Most AEs were
gastrointestinal disorders (n= 34, 97.1%), the most common
being diarrhoea (n= 29, 82.9%), nausea (n= 26, 74.3%) and
vomiting (n= 19, 54.3%). All 35 patients had an AE considered to
be causally related to AZD1208; diarrhoea (n= 24, 68.6%) and
nausea (n= 23, 65.7%) were the most common.
AEs of grade ≥3 were observed in 16 patients (45.7%). Four
patients (11.4%) discontinued the study due to an AE:
pneumonitis, n= 2; vomiting, n= 1; maculopapular rash, n= 1.
Sixteen patients (45.7%) required dose interruptions because of
AEs: 240mg, n= 2; 360 mg, n= 3; 540 mg, n= 6; 700 mg, n= 3;
800mg, n= 2. One patient in the 800mg cohort required dose
reduction because of AEs.
AEs of CTCAE grade ≥3 that occurred in ≥2 patients included:
fatigue (n= 4 [11.4%]), gamma-glutamyltransferase (GGT) increase
(n= 3 [8.6%]), abdominal pain (n= 2 [5.7%]) and anaemia (n= 2
[5.7%]). CTCAE grade ≥3 AEs causally related to AZD1208 occurred
in 10 patients (28.6%): 240mg, n= 3 (anaemia, alanine transami-
nase increased, GGT increased); 360 mg, n= 1 (lymphocyte
decreased); 540mg, n= 2 (vomiting, fatigue, lethargy); 700 mg,
n= 1 (nausea, fatigue); 800mg, n= 3 (fatigue, hyperglycaemia).
Eight patients (22.9%) experienced ≥1 SAE, none of which led to
discontinuation of AZD1208. SAEs that occurred in ≥2 patients
were dyspnoea (n= 2, 5.7%) and vomiting (n= 2, 5.7%). One
patient (2.9%) reported three treatment-related SAEs (vomiting,
fatigue, general physical health deterioration). One patient (2.9%)
died as a result of an AE (general deterioration of physical health)
that was not considered to be AZD1208-related by the
investigator.
No clinically signiﬁcant treatment-related changes in haematol-
ogy, clinical chemistry, vital signs, ECG or physical ﬁndings were
detected in any patient.
Four patients experienced DLTs: grade 3 fatigue (800 mg, n= 2),
grade 3 GGT increase (240 mg, n= 1) and grade 3 vomiting
(540mg, n= 1) (Table 3).
During the study, the 800mg dose was not expanded to the six
evaluable patients required to deﬁne MTD. As no dosing cohort
met these criteria, the MTD of AZD1208 could not be determined.
PK
AML dose-escalation study. The absorption of AZD1208 after a
single dose was rapid, with median time to maximum plasma
concentration (Tmax) of ~3 h and concentrations remaining high
until 24 h (Supplementary Table 2 and Supplementary Figure 1A).
A statistical power analysis demonstrated that following a single
dose, the maximum AZD1208 plasma concentration (Cmax)
(Supplementary Figure 2) and area under plasma
concentration–time curve (AUC0–t) (Supplementary Figure 3)
generally increased in proportion to the administered dose across
cohorts (range, 120–900mg).
Renal clearance was low across all cohorts, with <1% of the
administered dose eliminated unchanged in urine within 24 h.
Absorption of AZD1208 was likewise rapid after multiple doses, but
highly variable, with up to 10-fold differences in AZD1208
concentrations between individuals even within the same cohort
(Supplementary Table 2 and Supplementary Figure 1B).
Across the 120–900mg doses, 25% (4/16) of patients had
signiﬁcantly lower exposure at steady state compared with the ﬁrst
dose of AZD1208, and the percentage of patients with a lower
accumulation ratio increased with increasing dose (0% at 240mg to
67% at 900mg). However, 44% (7/16) of patients did show a marked
accumulation (>3-fold) across the doses. The number of patients
with higher accumulation decreased with increasing doses, and
exposure was highly variable, with one patient at 480mg having an
accumulation ratio of 3.6 and another a ratio of 0.36.
In general, both AUC over dosing interval (AUCtau) and Cmax
decreased with increasing doses. Power and ANOVA models
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revealed that whereas Cmax and AUC0–24 were dose proportional on
Cycle 1, Day 1, both Cmax and AUC0–24 were less than dose
proportional following multiple doses of AZD1208.
Solid tumour dose-escalation study. After a single dose, the
systemic exposure of AZD1208 (AUC and Cmax) was variable but
largely proportional with doses up to 700mg, and less than
proportional from 700–800mg (Fig. 1a and Supplementary
Table 3). After multiple dosing, exposure at all doses was similar,
with no increase in exposure with increasing doses (Fig. 1b and
Supplementary Table 3). Individual and geometric mean values for
Cmax and AUC are presented in Supplementary Figures 2 and 3,
respectively.
The mean half-life following a single dose was determined to be
37.2 h (min/max: 18.9 h/103 h). The elimination half-life after
multiple dosing could not be accurately determined.
Absorption following single dosing was moderate and variable,
with median Tmax achieved by ~5 h (range, 1.5–25 h); distribution
was moderate, and clearance low. In comparison, after multiple
dosing, the absorption was moderate, with median Tmax of ~4 h
Table 2. All-grade AEs with a frequency of >10% in the AML dose-escalation study (safety analysis set)
MedDRA preferred term AZD1208 120mg
n= 4
AZD1208 240mg
n= 6
AZD1208 480mg
n= 6
AZD1208 700mg
n= 7
AZD1208 900mg
n= 9
Total
N= 32
Patients with any AE 3 (75.0) 6 (100.0) 6 (100.0) 7 (100.0) 9 (100.0) 31 (96.9)
Gastrointestinal
Nausea 3 (75.0) 4 (66.7) 1 (16.7) 5 (71.4) 2 (22.2) 15 (46.9)
Diarrhoea 1 (25.0) 1 (16.7) 3 (50.0) 5 (71.4) 4 (44.4) 14 (43.8)
Vomiting 2 (50.0) 3 (50.0) 2 (33.3) 2 (28.6) 1 (11.1) 10 (31.3)
Abdominal pain 1 (25.0) 0 1 (16.7) 3 (42.9) 1 (11.1) 6 (18.8)
Stomatitis 1 (25.0) 1 (16.7) 3 (50.0) 0 0 5 (15.6)
Decreased appetite 0 1 (16.7) 0 2 (28.6) 1 (11.1) 4 (12.5)
General disorders
Fatigue 1 (25.0) 1 (16.7) 4 (66.7) 2 (28.6) 2 (22.2) 10 (31.3)
Oedema peripheral 1 (25.0) 1 (16.7) 3 (50.0) 2 (28.6) 2 (22.2) 9 (28.1)
Asthenia 1 (25.0) 0 1 (16.7) 1 (14.3) 2 (22.2) 5 (15.6)
Chills 0 1 (16.7) 0 1 (14.3) 2 (22.2) 4 (12.5)
Pyrexia 0 0 1 (16.7) 0 3 (33.3) 4 (12.5)
Vascular disorders
Hypotension 1 (25.0) 2 (33.3) 2 (33.3) 3 (42.9) 2 (22.2) 10 (31.3)
Blood and lymphatic system disorders
Febrile neutropenia 3 (75.0) 2 (33.3) 0 1 (14.3) 3 (33.3) 9 (28.1)
Respiratory disorders
Cough 0 1 (16.7) 1 (16.7) 4 (57.1) 2 (22.2) 8 (25.0)
Dyspnoea 0 1 (16.7) 2 (33.3) 2 (28.6) 2 (22.2) 7 (21.9)
Metabolic and nutritional disorders
Hypocalcaemia 1 (25.0) 1 (16.7) 1 (16.7) 3 (42.9) 1 (11.1) 7 (21.9)
Hypokalaemia 0 0 3 (50.0) 2 (28.6) 2 (22.2) 7 (21.9)
Hypomagnesaemia 1 (25.0) 1 (16.7) 2 (33.3) 2 (28.6) 1 (11.1) 7 (21.9)
Hypophosphataemia 1 (25.0) 0 2 (33.3) 1 (14.3) 2 (22.2) 6 (18.8)
Hyperglycaemia 0 0 2 (33.3) 1 (14.3) 2 (22.2) 5 (15.6)
Dehydration 0 0 0 0 4 (44.4) 4 (12.5)
Infections and infestations
Pneumonia 1 (25.0) 3 (50.0) 2 (33.3) 0 0 6 (18.8)
Nervous system disorders
Headache 0 0 3 (50.0) 1 (14.3) 0 4 (12.5)
Skin and subcutaneous disorders
Rash 0 0 1 (16.7) 1 (14.3) 2 (22.2) 4 (12.5)
Maculopapular rash 0 1 (16.7) 0 2 (28.6) 1 (11.1) 4 (12.5)
Renal and urinary disorders
Renal failure acute 0 1 (16.7) 2 (33.3) 1 (14.3) 0 4 (12.5)
Eye disorders
Vision blurred 1 (25.0) 0 3 (50.0) 0 0 4 (12.5)
Data are n (%) patients with AEs, sorted in decreasing frequency of preferred term (sorted by total column even when not reported). The number of evaluable
patients in each dose cohort was: 120 mg, n= 3; 240 mg, n= 3; 480 mg, n= 3; 700 mg, n= 4; 900mg, n= 3. Data include AEs with an onset date on or after the
date of ﬁrst dose and up to and including 30 days following the date of last dose of study medication. MedDRA version 17.0. was used. AE adverse event, AML
acute myeloid leukaemia, MedDRA Medical Dictionary for Regulatory Activities
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(range, 1.5–6 h), and clearance increased with increasing dose.
After a single dose, ~1% of the AZD1208 dose was eliminated in
urine over 72 h. After multiple dosing, on Day 15 0.5% of the
AZD1208 dose was observed in urine. Therefore, renal clearance
was negligible.
The activity of CYP3A4 was assessed by analysing
4-β-hydroxycholesterol levels in samples collected from ﬁve
patients at AZD1208 doses of 700 or 800mg. At both doses, the
levels of 4-β-hydroxycholesterol increased ~4-fold in all patients
on Day 15, compared with Day 1 (Supplementary Table 4),
indicating that CYP3A4 activity was induced by AZD1208.
PD
Reductions in pBAD S112 were observed in 7/17 patients with
evaluable bone marrow samples in the AML study (Fig. 2a).
Reductions in p4E-BP1 S65 were also observed in 3/11 patients
with evaluable bone marrow samples (Fig. 2b). However, the small
number of patients and variability in PD response in these data
must be noted.
Reductions of pBAD S112 in peripheral blood were more
frequently observed, with 9/10 patients across all dose levels
demonstrating ≥50% reduction from baseline (Fig. 2a). Decreases
in p4E-BP1 S65 were seen in the peripheral blood samples from
4/7 patients, with the greatest reductions observed at the highest
dose level of 900 mg (Fig. 2b). No correlation between dose,
exposure and biomarker effect was identiﬁed in these samples.
AML study—RPPA protein proﬁling in AML blasts
RPPA analysis of 171 proteins was performed on samples from six
patients (Supplementary Figure 1A). Based on the PD analyses
using MesoScale (Meso Scale Diagnostics, LLC, MD, USA) and
NanoPro (ProteinSimple, CA, USA), and on previous preclinical
investigations in AML cell lines,19 ﬁve phosphoproteins were
selected for analysis. Consistent with Fig. 2, there was hetero-
geneity in the protein level changes of phosphorylated 4E-BP1 S65
and BAD S112, measured using RPPA analysis (Supplementary
Figures 4A and 4B). Reductions were seen in 4E-BP1 S65 in three
patients (Supplementary Figure 4A) and in BAD S112 in four
patients (Supplementary Figure 4B). However, the small number of
patients and variability in response in these data must be noted.
Similarly, there was variability in the effects on phosphorylated
4E-BP1 T37/46, PRAS40 T246 and mTOR S2448 levels following
AZD1208 treatment (Supplementary Figures 5A–5D).
Efﬁcacy
AML dose-escalation study. There were no clinical responses
according to IWG criteria (Supplementary Table 5). A reduction in
circulating blasts occurred in several patients in the 120, 240 and
480mg dose cohorts. Only ﬁve patients who displayed decreases
in circulating blasts had evaluable biomarker samples, three of
whom showed a robust decrease in phosphoprotein levels.
However, several patients had reduced phosphoprotein levels
without a reduction in blasts. Resistant disease was the most
common treatment failure reason.
Solid tumour dose-escalation study. The best objective response,
as assessed by RECIST, was stable disease for ≥6 weeks (n= 13)
and progression (n= 14), with ﬁve patients non-evaluable for
response assessment (Supplementary Table 5). Patients were not
evaluable because they had stable disease response for <6 weeks
(n= 3) or incomplete post-baseline assessments (n= 2). The
objective response rate for the study was 0%. At Week 12, only
ﬁve patients were evaluable for tumour response assessments:
four patients had stable disease (120 mg, n= 1; 240mg, n= 2 and
540mg, n= 1); one had progressive disease (240 mg). Of note,
one patient who received treatment in the solid tumour dose-
escalation study had prostate cancer, and experienced a
considerable reduction in prostate-speciﬁc antigen (PSA) levels.T
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DISCUSSION
In the ﬁrst-in-human, dose-escalation study in patients with
heavily pretreated AML, AZD1208 was generally tolerated up to
doses of 700mg, but not tolerated at the highest 900mg dose. PK
data from this study suggest that AZD1208 absorption proﬁles for
patients who experienced DLTs were in the same range as those
of patients who did not have a DLT. It is unlikely that dose
interruptions contributed to any variability in repeat dosing PK as
the majority of the PK sampling timepoints occurred early in the
study (ﬁrst 15 days of treatment in Cycle 1). In the ﬁrst 15 days of
treatment there were minimal to no dose interruptions, and those
patients who had dose interruptions were not included in the PK
statistical analysis and hence did not contribute to the variability.
In the solid tumour dose-escalation study, AZD1208 was tolerated
as monotherapy at doses up to 700 mg QD, but not tolerated at
800mg QD. The MTD was not conﬁrmed in either study. It is
possible that the dose below 900mg was the MTD; however, as
we did not enrol the six patients required by the protocol, this
cannot be conﬁrmed.
Pan-PIM inhibition with AZD1208 appeared to be generally
tolerated in both studies, with the most common AEs affecting the
gastrointestinal tract. The patient in the AML study with GBS had a
history of E. coli bacteremia a few weeks before starting treatment
with AZD1208, and concurrent diseases including polyarthritis and
gout. Previous anticancer therapies included ruxolitinib, vidaza,
vosaroxin, decitabine, ﬂudarabine and cytarabine. In light of this
history, it was concluded that these factors may have contributed
to the development of GBS.
Another pan-PIM kinase inhibitor, LGH447, is currently in clinical
development and shows a manageable safety proﬁle
(ClinicalTrials.gov, NCT01456689).20 Among the 54 patients who
received LGH447 as monotherapy, there were eight DLTs
(thrombocytopenia, n= 4; fatigue, n= 2; hypophosphatemia,
n= 1; vasovagal syncope, n= 1), but most AEs were grade
Table 4. All-grade AEs with a frequency of >10% in the solid tumour dose-escalation study (safety analysis set)
MedDRA preferred term AZD1208 120
mg n= 3
AZD1208 240
mg n= 7
AZD1208 360
mg n= 6
AZD1208 540
mg n= 7
AZD1208 700
mg n= 6
AZD1208 800
mg n= 6
Total
N= 35
Patients with any AE 3 (100.0) 7 (100.0) 6 (100.0) 7 (100.0) 6 (100.0) 6 (100.0) 35 (100.0)
Gastrointestinal disorders
Diarrhoea 2 (66.7) 5 (71.4) 5 (83.3) 6 (85.7) 5 (83.3) 6 (100.0) 29 (82.9)
Nausea 1 (33.3) 6 (85.7) 3 (50.0) 7 (100.0) 5 (83.3) 4 (66.7) 26 (74.3)
Vomiting 0 (0.0) 6 (85.7) 1 (16.7) 5 (71.4) 4 (66.7) 3 (50.0) 19 (54.3)
Abdominal pain 0 (0.0) 3 (42.9) 2 (33.3) 2 (28.6) 1 (16.7) 0 (0.0) 8 (22.9)
Constipation 0 (0.0) 0 (0.0) 3 (50.0) 0 (0.0) 2 (33.3) 0 (0.0) 5 (14.3)
Blood and lymphatic system disorders
Anaemia 3 (100.0) 4 (57.1) 2 (33.3) 4 (57.1) 3 (50.0) 2 (33.3) 18 (51.4)
Thrombocytopenia 0 (0.0) 0 (0.0) 2 (33.3) 1 (14.3) 1 (16.7) 1 (16.7) 5 (14.3)
General disorders
Fatigue 0 (0.0) 2 (28.6) 3 (50.0) 3 (42.9) 4 (66.7) 5 (83.3) 17 (48.6)
Pyrexia 0 (0.0) 1 (14.3) 3 (50.0) 0 (0.0) 2 (33.3) 0 (0.0) 6 (17.1)
Metabolic and nutritional disorders
Decreased appetite 1 (33.3) 3 (42.9) 2 (33.3) 4 (57.1) 2 (33.3) 3 (50.0) 15 (42.9)
Hypoalbuminaemia 1 (33.3) 2 (28.6) 2 (33.3) 1 (14.3) 3 (50.0) 0 (0.0) 9 (25.7)
Hyperglycaemia 1 (33.3) 0 (0.0) 1 (16.7) 4 (57.1) 0 (0.0) 2 (33.3) 8 (22.9)
Hyponatraemia 0 (0.0) 0 (0.0) 1 (16.7) 3 (42.9) 1 (16.7) 0 (0.0) 5 (14.3)
Hypokalaemia 0 (0.0) 0 (0.0) 0 (0.0) 2 (28.6) 1 (16.7) 1 (16.7) 4 (11.4)
Investigationsa
Platelet count decreased 2 (66.7) 2 (28.6) 1 (16.7) 2 (28.6) 1 (16.7) 1 (16.7) 9 (25.7)
White blood cell count
decreased
2 (66.7) 3 (42.9) 1 (16.7) 2 (28.6) 1 (16.7) 0 (0.0) 9 (25.7)
GGT increased 0 (0.0) 2 (28.6) 1 (16.7) 2 (28.6) 0 (0.0) 1 (16.7) 6 (17.1)
Skin and subcutaneous tissue disorders
Dry skin 0 (0.0) 3 (42.9) 1 (16.7) 2 (28.6) 1 (16.7) 0 (0.0) 7 (20.0)
Respiratory, thoracic and mediastinal disorders
Dyspnoea 0 (0.0) 1 (14.3) 2 (33.3) 1 (14.3) 0 (0.0) 0 (0.0) 4 (11.4)
Psychiatric disorders
Insomnia 0 (0.0) 1 (14.3) 1 (16.7) 1 (14.3) 0 (0.0) 1 (16.7) 4 (11.4)
Musculoskeletal and connective tissue disorders
Musculoskeletal chest
pain
0 (0.0) 0 (0.0) 2 (33.3) 1 (14.3) 1 (16.7) 0 (0.0) 4 (11.4)
Data are n (%) patients with AEs, sorted in decreasing frequency of preferred term (sorted by total column even when not reported). The number of evaluable
patients in each dose cohort was: 120 mg, n= 3; 240mg, n= 5; 360mg, n= 2; 540 mg, n= 5; 700mg, n= 3; 800mg, n= 3. Data include AEs with an onset date
on or after the date of ﬁrst dose and up to and including 30 days following the date of last dose of study medication. MedDRA version 17.0 was used.
AE adverse event, CTCAE Common Terminology Criteria for Adverse Events, GGT gamma-glutamyltransferase, MedDRA Medical Dictionary for Regulatory
Activities. aBlood cell count decreases according to CTCAE version 4.0
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1 or 2.20 While pan-inhibition of PIM kinases with AZD1208 and
LGH447 appears to be tolerable, development of the pan-PIM
kinase inhibitor SGI-1776 in refractory prostate cancer and
relapsed/refractory non-Hodgkin lymphoma was discontinued
because of QTc prolongation (ClinicalTrials.gov, NCT00848601).
The lack of clinical responses in our AML and solid tumour dose-
escalation studies suggests that targeting the PIM pathway with
monotherapy may be insufﬁcient to impact refractory AML or
advanced solid malignancies. However, PD analysis of AZD1208
activity showed that, in a subset of patients, AZD1208 treatment
resulted in a reduction in the phosphorylation of PIM targets,
providing evidence for the biological activity of AZD1208 in
patients with refractory AML.
Pan-PIM inhibition has demonstrated therapeutic efﬁcacy in a
phase I study of LGH447 in 54 patients with relapsed/refractory
multiple myeloma (RRMM).20 The overall response rate was 10.4%,
with a minor response or greater in 20.8% and stable disease or
greater in 68.8%.20 Therefore, identifying the tumour types that
may be more sensitive to PIM inhibition will be important for
future PIM inhibitor trials. For instance, PIM overexpression has
been strongly associated with prostate cancer;21,22 indeed, one
patient who received treatment in the solid tumour dose-
escalation study had prostate cancer, and experienced a
considerable reduction in PSA levels. In MYC-driven prostate
cancer models, AZD1208 signiﬁcantly decreased tumour growth,
an effect that was accompanied by decreased cellular proliferation
and increased rates of apoptosis. AZD1208 treatment also
sensitised the prostate tumours to radiation.13
PIM kinase inhibitors may have the potential to be used in
combination with other therapies. For example, a phase Ib/II trial
of LGH447 in combination with the PI3K inhibitor, BYL719, is
underway in patients with RRMM (ClinicalTrials.gov,
NCT02144038). In preclinical tumour models, PIM kinase inhibitors
also have the ability to sensitise cancer cells to radiotherapy and
chemotherapy.23,24 For example, in a mouse xenograft model of
non-small-cell lung cancer, PIM inhibition sensitised cancer cells
to radiation23 and PIM antagonism in prostate cancer cells
sensitised the cells to the chemotherapeutic gemcitabine.24
Thus, PIM kinase inhibitors may be important in contexts where
PIM kinases are acting with other therapeutic targets to drive
oncogenic progression.
Preclinical studies of AML suggest that mTOR pathway
signalling and suppression of protein translation may play a part
in the mechanism of action of AZD1208.19 Consistent with these
studies, signiﬁcant reductions in 4EBP1 S65 were seen in a subset
of patients while more modest decreases in 4E-BP1 T37/46 and
mTOR S2448 were also noted. Given the lack of clinical efﬁcacy in
the AML trial, it is not clear to what extent effects on protein
translation contribute to PIM kinase activity in AML.
Based on the half-life of AZD1208 after a single dose, it was
predicted that multiple dosing would lead to accumulation of
AZD1208. However, exposure decreased with increasing doses
and with duration of dosing, indicating a possible change in
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clearance. Increased levels of 4-β-hydroxycholesterol following
multiple dosing of AZD1208 conﬁrmed that the increase in
clearance was due to induction of CYP3A4 enzymatic activity.
In conclusion, AZD1208 was generally tolerated in patients with
heavily pretreated AML and advanced solid malignancies in two
dose-escalation studies. AZD1208 increased CYP3A4 activity after
multiple dosing, resulting in increased drug clearance. There was
no clear evidence of antitumour activity with AZD1208 mono-
therapy, and the MTD was not established. Considering the
challenges in managing this potent increase in CYP3A4 activity, in
addition to the lack of observed responses in the clinical setting,
the development of AZD1208 was terminated. Still, PIM kinase
inhibition may be a relevant anticancer strategy, potentially in
combination with other agents.
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